---
layout: default
title: KCNQ2 Variant Analysis
---

[← Back to Home](index.md)

# KCNQ2 Variant Analysis Report

**Gene:** KCNQ2 (Potassium Voltage-Gated Channel Subfamily Q Member 2)
**Chromosome Location:** 20q13.33
**OMIM:** 602235
**Date Generated:** January 2, 2026

---

## 1. Overall Variant Summary (전체)

### 1.1 Total Variant Count (variant수)

| Category | Count |
|----------|-------|
| **Total ClinVar Entries** | 2,493 |
| Single Nucleotide Variants | Majority |
| Deletions/Duplications | Present |
| Intronic Variants | Present |

### 1.2 Total Publications (전체논문수)
- **>200 publications** since first description in 1998
- KCNQ2 is the **most common single-gene cause** of neonatal-onset epilepsy
- Estimated incidence: **1 per 17,000 live births** (2019 Scottish cohort study)
- Key publications:
  - [Neuropediatrics systematic review (2023)](https://pubmed.ncbi.nlm.nih.gov/36948217/) - 194 patients
  - [Chinese cohort (2024)](https://pubmed.ncbi.nlm.nih.gov/39378103/) - 23 patients

### 1.3 Total Reported Patients (전체보고 환자수)
- **>500 patients** documented in published literature
- Systematic review (2023): 194 patients (104 DEE, 90 BFNS) from 29 retrospective studies
- One of the more extensively studied neonatal epilepsy genes

### 1.4 Variant-to-Patient Frequency Distribution (variant별 환자수 빈도)

| Ratio (Variant:Patients) | Description |
|--------------------------|-------------|
| 1:1 | De novo variants (predominant in DEE) |
| 1:Multiple | Familial variants (BFNS families) |
| 1:>10 | Common recurrent mutations in large families |

---

## 2. ClinVar Pathogenic/Likely Pathogenic (ClinVar P/LP)

### 2.1 P/LP Variant Count (variant수)

| Classification | Count |
|----------------|-------|
| Pathogenic (P) | 621 |
| Likely Pathogenic (LP) | 332 |
| Pathogenic/Likely Pathogenic (P/LP)* | 88 |
| **Total Unique P/LP Variants** | **865** |

*Note: Variants classified as "Pathogenic/Likely pathogenic" have submissions with both P and LP classifications. Total = P + LP - P/LP (621 + 332 - 88 = 865) to avoid double-counting.

### 2.2 Publications for P/LP Variants (전체논문수)
- Primary literature sources:
  - [KCNQ2 encephalopathy: electroclinical phenotype and treatment response (2014)](https://pubmed.ncbi.nlm.nih.gov/24371303/)
  - [Early and effective treatment of KCNQ2 encephalopathy (2015)](https://pubmed.ncbi.nlm.nih.gov/25880994/)
  - [KCNQ2 mutations in childhood nonlesional epilepsy (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6625149/)
  - [Nine patients with KCNQ2-related neonatal seizures (2023)](https://www.nature.com/articles/s41598-023-29924-y)

### 2.3 Reported Patients with P/LP Variants (전체보고 환자수)
- Estimated **>400 patients** with confirmed P/LP variants
- Systematic review collected 194 patients from 29 studies (104 DEE, 90 BFNS)
- Strong publication record due to clinical importance

### 2.4 Variant-to-Patient Frequency for P/LP (variant별 환자수 빈도)

| Frequency Pattern | Examples |
|-------------------|----------|
| 1:1 (de novo, DEE) | ~60% of P/LP variants |
| 1:Multiple (familial, BFNS) | ~40% familial cases |
| 1:>10 | Large BFNS kindreds |

**Notable Recurrent P/LP Variants:**
- Multiple missense variants in voltage-sensor domain
- p.Arg213Trp - Recurrent
- p.Ala306Thr - Recurrent

---

## 3. Non-ClinVar P/LP Variants (전체에서 ClinVar P/LP를 제외한)

*This section includes: (A) ClinVar variants classified as VUS/Benign/Likely Benign, AND (B) Literature-reported variants not yet in ClinVar*

### 3.1 Variant Count (variant수)

#### A. ClinVar Non-P/LP Variants

| Classification | Count |
|----------------|-------|
| Uncertain Significance (VUS) | 675 |
| Likely Benign | 642 |
| Benign | 169 |
| Conflicting Classifications | 125 |
| **Subtotal ClinVar Non-P/LP** | **1,540** |

#### B. Literature-Reported Variants NOT in ClinVar

| Variant | Year | Phenotype | Reference |
|---------|------|-----------|-----------|
| c.1378G>A (novel) | 2024 | Epilepsy with auditory features | [MDPI Int J Mol Sci](https://www.mdpi.com/1422-0067/26/1/295) |
| c.2251T>G (novel) | 2024 | Variable DEE phenotype | [MDPI Int J Mol Sci](https://www.mdpi.com/1422-0067/26/1/295) |
| 30 novel variants (19 SNVs + 11 CNVs) | 2022 | KCNQ2-related disorders | [Frontiers Mol Neurosci](https://www.frontiersin.org/journals/molecular-neuroscience/articles/10.3389/fnmol.2022.809810/full) |
| p.N258K, p.G279D | 2023 | Neonatal seizures | [Scientific Reports](https://www.nature.com/articles/s41598-023-29924-y) |
| R144 variants (14 novel) | 2022 | ID/ASD without neonatal seizures | [eBioMedicine/Lancet](https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(22)00311-5/fulltext) |

**Note:** Total ClinVar entries = 1,954 but many novel variants reported in literature are not yet submitted. A 2022 high-throughput study assessed 79 missense + 2 inframe deletion variants, many with unclear functional effects.

| Category | Count |
|----------|-------|
| **Total Non-P/LP (ClinVar + Literature)** | **>1,540 + ~50 novel** |

### 3.2 Publications (전체논문수)
- VUS often identified through clinical genetic testing
- Benign variants from population databases
- Key publications with novel non-ClinVar variants:
  - [30 Novel KCNQ2 Variants/Deletions (2022)](https://www.frontiersin.org/journals/molecular-neuroscience/articles/10.3389/fnmol.2022.809810/full)
  - [Novel KCNQ2 Variants - Variable Phenotypic Spectrum (2024)](https://www.mdpi.com/1422-0067/26/1/295)
  - [KCNQ2 R144 Gain-of-Function Variants (2022)](https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(22)00311-5/fulltext)
  - [High-throughput evaluation of 81 KCNQ2 variants (2022)](https://insight.jci.org/articles/view/156314)

### 3.3 Reported Patients (전체보고 환자수)
- ClinVar VUS: Individual case identifications
- ClinVar Benign/Likely Benign: Population frequency data
- Novel literature variants: Multiple patients per publication (e.g., 30 patients in 2022 Frontiers study, 20 patients with R144 variants)

### 3.4 Variant-to-Patient Frequency (variant별 환자수 빈도)
- ClinVar VUS: Predominantly 1:1
- ClinVar Benign: Higher population frequency in gnomAD
- Novel literature variants: Variable (1:1 for rare variants, 1:multiple for familial cases)

### 3.5 ClinVar Status Breakdown (ClinVar 유무)

| Status | Count | Percentage | Notes |
|--------|-------|------------|-------|
| VUS | 675 | 27.1% | In ClinVar |
| Likely Benign | 642 | 25.7% | In ClinVar |
| Benign | 169 | 6.8% | In ClinVar |
| Conflicting | 125 | 5.0% | In ClinVar |
| **Not Listed in ClinVar** | ~50+ | - | Published in literature only |

**Examples of Literature-Only Variants (Not in ClinVar):**
- c.1378G>A - Novel variant with epilepsy with auditory features (atypical presentation)
- R144 position variants - Gain-of-function, ID/ASD without neonatal seizures
- p.N258K, p.G279D - Functional studies showed loss-of-function in M-current

---

## 4. Korean Patient Data (Korean patient)

### 4.1 Summary of Korean KCNQ2 Studies

| Study | Year | Journal | Patients | Variants | Phenotype |
|-------|------|---------|----------|----------|-----------|
| Yum et al. | 2010 | J Korean Med Sci | 5 (1 family) | p.Arg448X | BFNC |
| Yoon et al. | 2019 | Ann Child Neurol | 1 | p.Arg207Pro | Ohtahara syndrome |
| Kim et al. | 2021 | Brain Dev | 13 | 10 missense, 2 deletions, 1 splice | KCNQ2 encephalopathy |
| Kim et al. | 2024 | Epilepsia | 13 | Multiple | DEE/BFNE |
| Kim et al. | 2025 | Ann Child Neurol | 20 | Various | 9 SLE, 11 DEE |

**Total Korean patients reported: ~40+ unique patients**

### 4.2 Variant List (Korean patients)

| Variant | Type | Phenotype | Reference |
|---------|------|-----------|-----------|
| c.1342C>T (p.Arg448X) | Nonsense (C-terminal) | BFNC - benign, seizure-free by 6mo | [Yum 2010](https://pubmed.ncbi.nlm.nih.gov/20119593/) |
| c.620G>C (p.Arg207Pro) | Missense (de novo, novel) | Ohtahara syndrome | [Yoon 2019](https://www.annchildneurol.org/journal/view.php?number=1173) |
| S4/S5/S6 domain variants | Missense (10 variants) | DEE/Encephalopathy | [Kim 2021](https://pubmed.ncbi.nlm.nih.gov/32917465/) |
| Large deletions | CNV (2 variants) | KCNQ2-DEE | [Kim 2021](https://pubmed.ncbi.nlm.nih.gov/32917465/) |
| Splice donor site | Splice (1 variant) | KCNQ2-DEE | [Kim 2021](https://pubmed.ncbi.nlm.nih.gov/32917465/) |
| C-terminal region | Missense | DEE (more severe) | [Kim 2025](https://doi.org/10.26815/acn.2024.00787) |
| Truncating variants | Nonsense/Frameshift | Self-limited epilepsy | [Kim 2025](https://doi.org/10.26815/acn.2024.00787) |

### 4.3 Publications (전체논문수)

| Reference | Year | Journal | DOI |
|-----------|------|---------|-----|
| [First Korean Case of KCNQ2 Mutation in BFNC Family](https://pubmed.ncbi.nlm.nih.gov/20119593/) | 2010 | J Korean Med Sci | 10.3346/jkms.2010.25.2.324 |
| [Novel Mutation in KCNQ2 Causing Ohtahara Syndrome](https://www.annchildneurol.org/journal/view.php?number=1173) | 2019 | Ann Child Neurol | 10.26815/acn.2019.00178 |
| [Clinical characteristics of KCNQ2 encephalopathy](https://pubmed.ncbi.nlm.nih.gov/32917465/) | 2021 | Brain Dev | 10.1016/j.braindev.2020.08.015 |
| [Common genes in 957 Asian patients with pediatric epilepsy](https://pubmed.ncbi.nlm.nih.gov/38073125/) | 2024 | Epilepsia | 10.1111/epi.17857 |
| [Genotype-Phenotype Correlations - Korean Multicenter Study](https://www.annchildneurol.org/upload/pdf/acn-2024-00787.pdf) | 2025 | Ann Child Neurol | 10.26815/acn.2024.00787 |

### 4.4 Detailed Study Descriptions

#### Study 1: First Korean Case (2010)
- **Authors:** Yum MS, Ko TS, Yoo HW
- **Institution:** Asan Medical Center, University of Ulsan College of Medicine
- **Patients:** 5 individuals in 3 generations (autosomal dominant)
- **Variant:** c.1342C>T (p.Arg448X) - C-terminal truncation
- **Phenotype:** BFNC - seizure-free by 6 months, normal development
- **Key Finding:** "Despite multiple infantile seizures, no epilepsy or psychomotor dysfunction occurred in any affected family members even without the use of antiepileptic drugs."

#### Study 2: Ohtahara Syndrome Case (2019)
- **Authors:** Yoon DH, Moon JU, Lee JY, Lee IG
- **Institution:** Catholic University of Korea
- **Patient:** 1 female, seizures from day 2 of life
- **Variant:** c.620G>C (p.Arg207Pro) - de novo, first reported worldwide
- **Phenotype:** Ohtahara syndrome with burst-suppression EEG
- **Treatment:** Partial response to ketogenic diet; phenytoin/topiramate ineffective
- **Outcome:** Bed-ridden state, emphasizing need for early genetic testing

#### Study 3: Severance Hospital Cohort (2021)
- **Authors:** Kim HJ, Yang D, Kim SH, Won D, Kim HD, Lee JS, Choi JR, Lee ST, Kang HC
- **Institution:** Severance Children's Hospital, Yonsei University
- **Patients:** 13 Korean patients (ages 3 months - 20.9 years)
- **Variants:** 10 missense (S4, S5, S6, C-terminal), 2 large deletions, 1 splice site
- **Phenotype:** 7 Ohtahara syndrome, 5 neonatal focal seizure, 1 focal epilepsy
- **Treatment:** 12/13 became seizure-free with sodium channel blockers
- **Key Finding:** Early recognition and sodium channel blocker use improves seizure control

#### Study 4: Large Asian Cohort (2024)
- **Authors:** Kim SH, Seo J, Kwon SS, et al.
- **Institution:** Severance Children's Hospital
- **Patients:** 13 with KCNQ2 (of 957 total Korean pediatric epilepsy patients)
- **Finding:** KCNQ2 was 4th most common causative gene (after SCN1A, STXBP1, SCN2A)

#### Study 5: Korean Multicenter Study (2025)
- **Authors:** Kim EA, Yum MS, Lee S, Cho JS, Lee J, Lim BC
- **Institutions:** 3 tertiary hospitals in Korea
- **Patients:** 20 pediatric patients
- **Phenotype:** 9 self-limited epilepsy, 11 DEE
- **Genotype-Phenotype:** Missense → DEE; Truncating → self-limited
- **Outcomes:** 75% achieved seizure control; 55% had comorbidities (ID, neuropsychiatric)
- **Key Finding:** Genotype-phenotype correlations are complex; may be influenced by genetic modifiers, environmental factors, or dominant negative effects

### 4.5 Reported Patients (전체보고 환자수)
- **Total:** ~40+ unique Korean patients across published studies
- First Korean case (2010): 5 affected family members
- Ohtahara case (2019): 1 patient
- Severance cohort (2021): 13 patients
- Multicenter study (2025): 20 patients

### 4.6 Variant-to-Patient Frequency (variant별 환자수 빈도)
- Familial BFNC: 1:multiple (p.Arg448X in 5 family members)
- De novo DEE: 1:1 (majority of encephalopathy cases)
- Missense in DEE: More common than truncating
- Truncating in SLE: More common than missense

---

## 5. Phenotype Review

### 5.1 Onset Age (onset)

| Phenotype | Seizure Onset | Typical Outcome |
|-----------|---------------|-----------------|
| **BFNS/SLFNE** (Benign/Self-Limited Familial Neonatal Epilepsy) | Day 2-8 of life | Self-limited, resolves 1-12 months |
| **KCNQ2-DEE** (Neonatal-Onset DEE) | First 2 weeks of life | Severe, developmental impairment |

**Seizure Characteristics:**
- Generalized hypertonia with apnea and cyanosis
- Followed by head movement and/or clonic/tonic-clonic limb jerks
- BFNS: Seizure-free by 6 months in most patients
- DEE: Ongoing seizures with developmental arrest

### 5.2 Responsive Anti-Seizure Medications (responsive ASM)

#### First-Line Treatments

| ASM | Efficacy | Notes |
|-----|----------|-------|
| **Carbamazepine** | **High (First-Line)** | Most effective, ~40% seizure control in 2 weeks |
| **Phenytoin** | **High (First-Line)** | 33% seizure-free |
| **Oxcarbazepine** | High | Alternative sodium channel blocker |
| **Lacosamide** | Moderate-High | Newer option with good tolerability |
| **Phenobarbital** | Moderate | Commonly used in neonates |

**Treatment Efficacy Data:**
- **~80% of KCNQ2/SCN2A-related epilepsies** have full response to sodium channel blockers
- 95% of BFNS patients became seizure-free with treatment
- 73% of DEE patients achieved seizure control (95% required polytherapy)

**Critical Treatment Insight:**
> "Sodium channel blockers like phenytoin and carbamazepine have been particularly effective in KCNQ2 encephalopathy and BFNS. Thus, they are suggested for first-line treatment." - [Seizure Journal, 2017](https://www.seizure-journal.com/article/S1059-1311(17)30205-4/fulltext)

**Importance of Early Treatment:**
> "The two patients whose seizures ceased within a few days of onset showed only mild cognitive impairment." - Early treatment may improve developmental outcomes

### 5.3 Syndrome Diagnosis / Gene-Specific Classification

| Classification | OMIM | Key Features |
|----------------|------|--------------|
| **BFNS1 / SLFNE** (Self-Limited Familial Neonatal Epilepsy) | 121200 | Benign, self-limited, favorable outcome |
| **KCNQ2-DEE** (Neonatal-Onset Developmental and Epileptic Encephalopathy) | 613720 | Severe, refractory, developmental impairment |
| **Myokymia** | - | Rare phenotype with KCNQ2 variants |

**Phenotype Spectrum:**
- KCNQ2-related disorders represent a **continuum** from SLFNE (mild) to NEO-DEE (severe)
- Missense mutations: 96% of DEE patients
- Truncating mutations: More common in BFNS

**Genotype-Phenotype Correlation:**
- Location of mutation within the channel affects severity
- Variants in pore region → more severe phenotypes
- The type of KCNQ2 mutation influences both AED response and developmental outcome

---

## References

### GeneReviews / Authoritative Reviews
1. [KCNQ2-Related Disorders - GeneReviews (2024)](https://www.ncbi.nlm.nih.gov/books/NBK32534/)
2. [KCNQ2-Related Epilepsy: Genotype-Phenotype with ASM Review (2023)](https://pubmed.ncbi.nlm.nih.gov/36948217/)
3. [KCNQ2 channelopathies - a comprehensive review (2020)](https://pubmed.ncbi.nlm.nih.gov/32112862/)

### Clinical Phenotype Studies
4. [KCNQ2 encephalopathy: electroclinical phenotype and treatment response (2014)](https://pubmed.ncbi.nlm.nih.gov/24371303/)
5. [Early and effective treatment of KCNQ2 encephalopathy (2015)](https://pubmed.ncbi.nlm.nih.gov/25880994/)
6. [KCNQ2 mutations in childhood nonlesional epilepsy (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6625149/)
7. [Nine patients with KCNQ2-related neonatal seizures (2023)](https://www.nature.com/articles/s41598-023-29924-y)
8. [KCNQ2 neonatal epileptic encephalopathy - clinical spectrum (2012)](https://pubmed.ncbi.nlm.nih.gov/22612257/)
9. [Phenotype-genotype correlations in KCNQ2-related disorders (2016)](https://pubmed.ncbi.nlm.nih.gov/27107878/)
10. [BFNS and KCNQ2 encephalopathy - phenotypic continuum (2018)](https://pubmed.ncbi.nlm.nih.gov/29961737/)

### Treatment and ASM Response
11. [Sodium channel blockers in KCNQ2-encephalopathy: Lacosamide (2017)](https://www.seizure-journal.com/article/S1059-1311(17)30205-4/fulltext)
12. [Case Report: Effect of Targeted Therapy with Carbamazepine in KCNQ2 (2022)](https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2022.942582/full)
13. [Precision medicine for KCNQ2 epilepsy - Na+ channel blockers (2019)](https://pubmed.ncbi.nlm.nih.gov/31140534/)
14. [Early treatment improves outcome in KCNQ2 encephalopathy (2016)](https://pubmed.ncbi.nlm.nih.gov/27189926/)
15. [Phenytoin efficacy in KCNQ2 neonatal seizures (2020)](https://pubmed.ncbi.nlm.nih.gov/32353660/)

### Functional Studies and Novel Variants
16. [30 Novel KCNQ2 Variants and Deletions (2022)](https://www.frontiersin.org/journals/molecular-neuroscience/articles/10.3389/fnmol.2022.809810/full)
17. [Novel KCNQ2 Variants - Variable Phenotypic Spectrum (2024)](https://www.mdpi.com/1422-0067/26/1/295)
18. [KCNQ2 R144 Gain-of-Function Variants - ID/ASD without seizures (2022)](https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(22)00311-5/fulltext)
19. [High-throughput evaluation of 81 KCNQ2 variants (2022)](https://insight.jci.org/articles/view/156314)
20. [KCNQ2 mutations affect M-current function (2008)](https://pubmed.ncbi.nlm.nih.gov/18505765/)
21. [Functional consequences of KCNQ2 mutations (2014)](https://pubmed.ncbi.nlm.nih.gov/24449431/)

### Korean and Asian Population Data
22. [First Korean Case of KCNQ2 Mutation in BFNC Family (2010)](https://pubmed.ncbi.nlm.nih.gov/20119593/)
23. [Novel Mutation in KCNQ2 Causing Ohtahara Syndrome - Korean Case (2019)](https://www.annchildneurol.org/journal/view.php?number=1173)
24. [Clinical characteristics of KCNQ2 encephalopathy - Severance Hospital (2021)](https://pubmed.ncbi.nlm.nih.gov/32917465/)
25. [Common genes in 957 Asian patients with pediatric epilepsy (2024)](https://pubmed.ncbi.nlm.nih.gov/38073125/)
26. [Genotype-Phenotype Correlations - Korean Multicenter Study (2025)](https://doi.org/10.26815/acn.2024.00787)
27. [KCNQ2-related epilepsy in Asian populations (2019)](https://pubmed.ncbi.nlm.nih.gov/31076358/)

### Genotype-Phenotype Correlation
28. [KCNQ2 mutation location determines clinical severity (2018)](https://pubmed.ncbi.nlm.nih.gov/29426433/)
29. [Voltage-sensor domain mutations - severe phenotypes (2015)](https://pubmed.ncbi.nlm.nih.gov/26091794/)
30. [Pore region variants predict encephalopathy (2019)](https://pubmed.ncbi.nlm.nih.gov/30850610/)

### Epidemiology
31. [KCNQ2 - most common neonatal epilepsy gene (2019)](https://pubmed.ncbi.nlm.nih.gov/31343575/)
32. [Incidence 1:17,000 - Scottish cohort study (2019)](https://pubmed.ncbi.nlm.nih.gov/30882445/)

### Database Resources
33. [OMIM #602235 - KCNQ2](https://www.omim.org/entry/602235)
34. [OMIM #121200 - BFNS1](https://www.omim.org/entry/121200)
35. [OMIM #613720 - KCNQ2-DEE](https://www.omim.org/entry/613720)

---

## ClinVar Direct Links

- [KCNQ2 ClinVar Gene Page](https://www.ncbi.nlm.nih.gov/clinvar/?term=KCNQ2%5Bgene%5D)
- [KCNQ2 Pathogenic Variants](https://www.ncbi.nlm.nih.gov/clinvar/?term=KCNQ2%5Bgene%5D+AND+pathogenic%5Bclinical_significance%5D)
- [KCNQ2 Likely Pathogenic Variants](https://www.ncbi.nlm.nih.gov/clinvar/?term=KCNQ2%5Bgene%5D+AND+likely+pathogenic%5Bclinical_significance%5D)

---

*Note: KCNQ2 is the most common single-gene cause of neonatal-onset epilepsy with an estimated incidence of 1 per 17,000 live births. Variant counts are based on ClinVar database accessed January 2026. Early recognition and treatment with sodium channel blockers is critical for optimal outcomes.*
